NCT01266135View on ClinicalTrials.gov

Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

QAX576

QAX576 10 mg/kg intravenous infusion

DRUG

Placebo

Placebo to QAX576 intravenous infusion

Trial Locations (10)

15219

Novartis Investigative Site, Pittsburgh

27710

Novartis Investigative Site, Durham

32611

Novartis Investigative Site, Gainesville

32803

Novartis Investigative Site, Orlando

37203

Novartis Investigative Site, Nashville

78229

Novartis Investigative Site, San Antonio

02115

Novartis Investigative Site, Boston

CB2 2QQ

Novartis Investigative Site, Cambridge

LE3 9QP

Novartis Investigative Site, Leicester

SW3 6PH

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY